Relationship between increased maternal serum free human chorionic gonadotropin levels in the second trimester and adverse pregnancy outcomes: a retrospective cohort study.

Publisher: BioMed Central Country of Publication: England NLM ID: 101088690 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6874 (Electronic) Linking ISSN: 14726874 NLM ISO Abbreviation: BMC Womens Health Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2001-

Pregnancy Trimester, Second*/blood ; Pregnancy Outcome*/epidemiology ; Chorionic Gonadotropin, beta Subunit, Human*/blood; Humans ; Pregnancy ; Female ; Retrospective Studies ; Adult ; Pregnancy Complications/blood ; Pregnancy Complications/epidemiology ; China/epidemiology ; Pre-Eclampsia/blood ; Pre-Eclampsia/epidemiology ; Cohort Studies ; Polyhydramnios/blood ; Polyhydramnios/epidemiology ; Chorionic Gonadotropin/blood ; Hyperlipidemias/blood ; Hyperlipidemias/epidemiology

Background: A retrospective cohort study was conducted to collect the data of pregnant women who received hospital delivery in Hangzhou Women's Hospital from January 2018 to December 2020, and who participated in the second trimester (15-20 ⁺⁶  weeks) of free beta human chorionic gonadotropin (free β-hCG). And the study was conducted to explore the relationship between maternal serum free β-hCG and adverse pregnancy outcomes (APO).
Methods: We retrospectively analyzed the clinical data of 1,978 women in the elevated maternal serum free β-hCG group (free β-hCG ≥ 2.50 multiples of the median, MoM) and 20,767 women in the normal group (0.25 MoM ≤ free β-hCG < 2.50 MoM) from a total of 22,745 singleton pregnancies, and modified Poisson regression analysis was used to calculate risk ratios (RRs) and 95% confidence intervals (CI) of the two groups.
Results: The gravidity and parity in the elevated free β-hCG group were lower, and the differences between the groups were statistically significant (all, P < 0.05). The risks of polyhydramnios, preeclampsia, and hyperlipidemia, were increased in women with elevated free β-hCG levels (RRs: 1.996, 95% CI: 1.322-3.014; 1.469, 95% CI: 1.130-1.911 and 1.257, 95% CI: 1.029-1.535, respectively, all P < 0.05), intrauterine growth restriction (IUGR) and female infants were also likely to happen (RRs = 1.641, 95% CI: 1.103-2.443 and 1.101, 95% CI: 1.011-1.198, both P < 0.05). Additionally, there was an association between elevated AFP and free β-hCG levels in second-trimester (RR = 1.211, 95% CI: 1.121-1.307, P < 0.001).
Conclusions: APOs, such as polyhydramnios, preeclampsia, and hyperlipidemia, were increased risks of elevated free β-hCG levels, IUGR and female infants were also likely to happen. Furthermore, there was an association between elevated AFP levels and elevated free β-hCG levels in second-trimester. We recommend prenatal monitoring according to the elevated maternal serum free β-hCG level and the occurrence of APO.
(© 2024. The Author(s).)

Fetal Diagn Ther. 2019;46(3):187-192. (PMID: 30726846)
J Obstet Gynaecol Can. 2015 Feb;37(2):111-6. (PMID: 25767942)
J Matern Fetal Neonatal Med. 2019 Oct;32(19):3191-3196. (PMID: 29642747)
Clin Chem Lab Med. 2019 Nov 26;57(12):1956-1967. (PMID: 31343977)
Prenat Diagn. 1996 May;16(5):431-5. (PMID: 8844001)
Reprod Sci. 2013 Sep;20(9):1038-45. (PMID: 23439616)
Placenta. 2020 Jan 1;89:67-77. (PMID: 31704631)
Ginekol Pol. 2023;94(2):158-166. (PMID: 36597745)
Sci Rep. 2022 Mar 8;12(1):4056. (PMID: 35260712)
Cureus. 2022 Mar 13;14(3):e23115. (PMID: 35425672)
BMC Pregnancy Childbirth. 2020 Dec 14;20(1):776. (PMID: 33317474)
Placenta. 2010 Apr;31(4):277-81. (PMID: 20132984)
Am J Obstet Gynecol. 2003 Sep;189(3):775-81. (PMID: 14526312)
Clin Exp Hypertens. 2023 Dec 31;45(1):2175848. (PMID: 36849437)
Sultan Qaboos Univ Med J. 2013 Feb;13(1):57-62. (PMID: 23573383)
Eur J Obstet Gynecol Reprod Biol. 1998 Jul;79(1):103-5. (PMID: 9643414)
Am J Obstet Gynecol. 2022 Sep;227(3):497.e1-497.e13. (PMID: 35487327)
Diabetes Care. 2010 Mar;33(3):676-82. (PMID: 20190296)
Int J Mol Sci. 2022 Jan 26;23(3):. (PMID: 35163303)
Health Sci Rep. 2024 Feb 25;7(2):e1903. (PMID: 38410499)
BMC Pregnancy Childbirth. 2020 Oct 15;20(1):621. (PMID: 33059628)
Hua Xi Yi Ke Da Xue Xue Bao. 1996 Jun;27(2):122-5. (PMID: 9389023)
Int J Mol Sci. 2023 Apr 21;24(8):. (PMID: 37108840)
J Obstet Gynaecol Can. 2008 Oct;30(10):918-932. (PMID: 19038077)
Med Sci Monit. 2022 Apr 13;28:e935573. (PMID: 35414638)
Akush Ginekol (Sofiia). 2002;41(6):3-12. (PMID: 12577497)
Arch Gynecol Obstet. 2019 Mar;299(3):713-718. (PMID: 30706180)
Exp Biol Med (Maywood). 2022 May;247(10):822-831. (PMID: 35238224)
Sci Rep. 2023 Jan 21;13(1):1228. (PMID: 36681713)
Obstet Gynecol. 2013 Oct;122(4):918-930. (PMID: 24084566)
Am J Obstet Gynecol. 2006 Mar;194(3):821-7. (PMID: 16522419)
FASEB J. 2013 Apr;27(4):1309-21. (PMID: 23233533)

2021KY258 Zhejiang Medicine and Health Scientific Research Project; LBY23H200009 The Joint Fund Project of Zhejiang Provincial Natural Science Foundation of China

Keywords: Adverse pregnancy outcomes; Free beta-subunit human chorionic gonadotropin; Maternal serum; Retrospective cohort study; Risk ratios

0 (Chorionic Gonadotropin, beta Subunit, Human)
0 (Chorionic Gonadotropin)

Date Created: 20240604 Date Completed: 20240604 Latest Revision: 20240612

20240613

PMC11149239

10.1186/s12905-024-03105-z

38835013